Clinical trial
A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of…
NCT00102609 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00102609 |
|---|---|
| Title | A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma |
| Official title | A Phase I Study to Determine the Dose of the Combination of Yondelis and Doxorubicin for Which Neutropenia is Manageable With the Support of Granulocyte-Colony Stimulation Factor in Subjects With Recurrent or Persistent Soft Tissue Sarcoma |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Collaborators | PharmaMar Industry PharmaMar S.A.U. |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Soft Tissue Sarcoma, Sarcoma, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type |
| Intervention type | Drug |
| Interventions | Doxorubicin, Trabectedin, Dexamethasone |
| Enrollment | 41 |
| Start date | Apr 1, 2005 |
| Completion | Oct 1, 2007 |
| First posted | Feb 1, 2005 |
| Last update posted | Jan 10, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: